SNDX Syndax Pharmaceuticals Inc

Just another day bashing $SNDX management for not exiting via M&A when the opportunity presented itself. M&A exit is a strategy that has historically maximizes shareholder value versus GIA 100% of the time (in oncology, 92% of the time in non-oncology). Hopefully the IPF data is good. We've waited this long so why not a few more months. SNDX is down 14% year to date while the $XBI is up 32.7%. We are unaware of any peer commercial-stage oncology focused bio (or non-oncology for that matter) that trades at a lower multiple of analyst consensus revenue estimates with gross margins north of 90%, with only 1 exception $ARDX We hope SNDX considers shareholders above all else as well as patients who can only benefit via scale to help control costs via $INCY acquisition. Don't worry about SNDX's CEO. Simple analysis proves he does better via annual share grants in spite of share price declines (read our 3/31/26 post). This is not investment advice. $IBB

$SNDX Added at $13.76. May dip lower but wanted to capitalize on the disconnect. Quick rebound candidate with additional (un-related) data readout this quarter. Approved drugs with multiple indications make this Disconnect Buy an easy one. Last Disconnect Buy $ICU is already up 28% in just over a week. Follow/Subscribe for more suggestions/perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers! $XBI

H.C. Wainwright reiterated $SNDX Buy; PT $38 $KURA $ABBV - RHHBY OTSKY BMY INCY AVLN SNY H.C. Wainwright said in its note: Ahead of 3Q earnings, we completed a deeper diligence effort around NPM1m AML biology and market dynamics that provides a granular understanding of the unique headwinds and underappreciated opportunities within R/R NPM1m AML. Our work centered on revisiting commercial assumptions for the NPM1m AML market as compared to KMT2Ar. We spoke to leading hematologist-oncologists to gain a quick perspective on how targeted therapies like Revuforj are being integrated into existing treatment algorithms, and how those protocols diverge between different genetic subsets of AML in both the frontline and R/R setting. Overall, we came away with a nuanced view of the NPM1m market where frequent actionable co-mutations create headwinds from established targeted therapies in treatment sequencing, rather than from menin inhibitors.

$SNDX drop on this Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis "Trial did not meet the primary endpoint of annualized rate of FVC decline"

$SNDX market cap, analyst consensus revenue estimates & related multiples v $SRRK whose first therapy was approved by the FDA last week. It is interesting to note analysts expect SRRK's therapies to generate roughly 10% more revenues than SNDX for the years FY29 - FY35 yet SRRK trades at a 4X higher market cap? Related revenue multiples are also provided. This is not investment advice but simple analytics suggest either SNDX is undervalued or SRRK is overvalued. We c/b wrong so we're genuinely curious if any SNDX or SRRK investor reads the attachments otherwise Don't worry about SNDX's CEO because he will likely get another generous share grant come this February just like the last few years. Revisit our post from last March where we documented how he takes home more in spite of meaningful drops in share price. Why create synergy & scale to best control costs for these cancer patients by selling to $INCY when one can make so much money GIA in spite of a falling share price? ​$XBI $IBB

$SNDX Sorry to go on a long diatribe-and many here won't understand where I'm coming from. But IMO the debt deal $SNDX did was a very bad call. Having watched it trade-You can clearly see how the stocks trading changed once conversations started w bankers around the deal. How it's correlation to XBI stopped- how the short position dropped 5mm shares on 5/31 reflected the deal closing and then capping stock near exercise price. IMO $SNDX should not have taken GIA strategy. Look to previous posts to further understand. They should have pursued acquisition; but mgmt. preferred being granted RSU's-salary etc. and issued debt to pursue buildout. Were they just naive w debt deal and what comes with it? Trusting the underwriters? Or they didn't care? Trimmed a bunch higher and will buy back if there is a reason-like revenue numbers backing up the talk. Meanwhile $KURA CEO actively buying $2.5M stock in the open market-with more to come Plz. bring on the criticism.. Thx.

Down 19.6% after hours: $SNDX tanked to $13.30 after its Phase 2 lung-disease trial missed and the company shelved the program. Biotech's worst kind of news.

Syndax Pharmaceuticals announced that axatilimab failed to meet the primary endpoint in the Phase 2 MAXPIRe trial for idiopathic pulmonary fibrosis (IPF). The study did not achieve its primary goal of reducing the annualized rate of decline in forced vital capacity (FVC), prompting the company to discontinue development of axatilimab for this indication. The trial enrolled 145 patients across 62 sites in 14 countries, randomizing them 2:1 to receive axatilimab at 0.3 mg/kg or placebo every two weeks for 26 weeks. Despite the efficacy failure, the drug was generally well tolerated, with a safety profile comparable to placebo, no new safety signals and no treatment-related fatal adverse events in either group. Syndax said the results will not affect ongoing axatilimab trials for other indications. The drug is FDA-approved for chronic graft-versus-host disease (cGVHD) in adult and pediatric patients weighing at least 40 kg after failure of at least two prior lines of systemic therapy. $SNDX

$SNDX (Syndax, maker of approved leukemia drug Revuforj and cGVHD drug Niktimvo) said its Phase 2 trial of Niktimvo in lung disease IPF missed its primary endpoint; it is ending IPF work, once billed as a multi-billion-dollar target. The IPF miss does not touch Niktimvo's approved cGVHD sales ($60.3M net revenue in 2Q26, giving Syndax $18.1M of collaboration revenue) or its other trials. But at June 30 total liabilities were $688.6M, above the $575.1M in cash, and stockholders' equity was $15.1M. Next: frontline cGVHD Phase 2 data in 4Q26.

$SNDX painful, soon trading at Kura's valuation (own half of its menin inhib, and some pipeline), vs SNDX owning Revu and half of Nikt...

$SNDX waiting for my own comeback – Topline data expected in 4Q26 from Phase 2 trials of axatilimab in IPF and frontline cGVHD –

$SNDX I am trapped in this crap just because I believe ins scarcity but the management is dogshit

$SNDX | Snapshot 📊⚡ • Business: Syndax Pharmaceuticals is a commercial-stage biotech advancing targeted therapies for blood cancers and immune-mediated diseases. • Commercial Assets: Commercializing Revuforj (menin inhibitor for acute leukemia) and Niktimvo (anti-CSF-1R antibody for chronic GVHD). • Bias & Conviction: Bullish Trendline Reversal | Moderate-High Conviction (Bouncing off primary trendline support at $18.15 with back-to-back Jan 2027 bullish LEAP call sweeps). 🎯 Key Levels: 🐂 Bull Trigger: $19.14 🚀 Targets: $22.17 / $25.00 / $25.50 🛡️ Support: $18.15 / $18.00 ⚠️ Risk: $17.50 / $16.50 🔥 Volume & Flow: • 🟢 Repeated institutional call buying in Jan 2027 $22 and $24 Calls at/above ask ($110.7K+ total premium). #SNDX #stocks #finance #hovdid

$SNDX Syndax is dropping the IPF program for axatilimab. The Phase 2 MAXPIRe trial missed its primary endpoint, the annualized rate of decline in forced vital capacity, and the company says it will not move forward in IPF. Safety was not the issue. Profile was comparable to placebo, no new signals, and no treatment-related deaths in either arm. The 26-week study ran across 62 sites in 14 countries. Axatilimab is already approved as Niktimvo for chronic graft-versus-host disease after at least two prior therapies, and those cGVHD trials are still going, with readouts expected later this year and early 2028. Shares closed down 2.6 percent at 16.55, then fell about 17 percent in extended trading.

$SNDX well it's definitely time to sell the company now. Won't get the return we hoped, but they pinned their hopes of going big with IPF. Especially with JNJ's product on their heels for revumenib.

$SNDX 🏥 Syndax Pharmaceuticals, Inc. announced topline results from the Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis, which did not meet the primary endpoint of annualized rate of FVC decline. Prioritized by relevance

$SNDX options are always funky on this one. I could sell and I did, some 25c’s for this month at 20 but couldn’t sell out of the 20c’s I bought a while back for 75 🤔

$SNDX lots of 20 P’s still sitting there. Let’s see if they want those in the money come Friday.